AZ, Daiichi’s targeted breast cancer therapy on target
Patients achieved a disease control rate of 97.3%
Read More
Tag: Daiichi
LifeArc licenses discovery programme to Daiichi Sankyo
The deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.
Read More
AstraZeneca and Daiichi sign $6.9bn cancer drug deal
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
